Debt-to-equity of CNS Pharmaceuticals, Inc. from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: CNS Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2020 to 30 Sep 2025.
CNS Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 22%.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

CNS Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	22%	+257%		30 Sep 2025
Q2 2025	32%	+187%		30 Jun 2025
Q1 2025	99%	+348%		31 Mar 2025
Q4 2024	2415%	+10412%		31 Dec 2024
Q3 2024	-235%	-372%	-272%	30 Sep 2024
Q2 2024	-155%	-220%	-338%	30 Jun 2024
Q1 2024	-249%	-286%	-776%	31 Mar 2024
Q4 2023	-7997%	-8017%	-39680%	31 Dec 2023
Q3 2023	137%	+122%	+803%	30 Sep 2023
Q2 2023	65%	+48%	+271%	30 Jun 2023
Q1 2023	37%	+18%	+94%	31 Mar 2023
Q4 2022	20%	-2%	-10%	31 Dec 2022
Q3 2022	15%	-2%	-12%	30 Sep 2022
Q2 2022	18%	+2%	+14%	30 Jun 2022
Q1 2022	19%	+4%	+30%	31 Mar 2022
Q4 2021	22%	+11%	+94%	31 Dec 2021
Q3 2021	17%	+10%	+139%	30 Sep 2021
Q2 2021	15%	+2%	+14%	30 Jun 2021
Q1 2021	15%			31 Mar 2021
Q4 2020	12%			31 Dec 2020
Q3 2020	7%			30 Sep 2020
Q2 2020	13%			30 Jun 2020

* An asterisk sign (*) next to the value indicates that the value is likely invalid.